The companies' TargeTron technology involves targeted insertion of a "TargeTron group II" intron into a host genome, resulting in "permanent" target gene knockout into a variety of prokaryotic genomes, said the statement. Targeted insertion is "more than 90 percent successful" and will work "across a broad range" of prokaryotes, the company added.
Future systems are planned for targeted plant and mammalian gene disruption, Sigma said.